Arcturus Therapeutics Ltd. Research and Development Expense
Arcturus Therapeutics Ltd. reported Research and Development Expense of $7.32 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2019-05-13
- Arcturus Therapeutics Ltd. research and development expense for the quarter ending 2019-03-31 was $7.32M, a 85.84% increase year-over-year.
- Arcturus Therapeutics Ltd. research and development expense for the quarter ending 2018-12-31 was $4.85M, a 11.35% increase year-over-year.
- Arcturus Therapeutics Ltd. research and development expense for the quarter ending 2018-09-30 was $3.97M, a 11.39% increase year-over-year.
- Arcturus Therapeutics Ltd. research and development expense for the quarter ending 2018-06-30 was $4.22M, a 12.10% increase year-over-year.
- Arcturus Therapeutics Ltd. research and development expense for fiscal 2018 was $16.98M, a 6.68% increase from fiscal 2017.
- Arcturus Therapeutics Ltd. research and development expense for fiscal 2017 was $15.92M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed | Research and Development Expense 71 month |
|---|---|---|---|---|---|---|---|
| 2019-03-31 | $7.32M 10-Q · filed 2019-05-13 | $12.17M derived: sum of 2 quarters · filed 2019-05-13 | $16.14M derived: sum of 3 quarters · filed 2019-05-13 | $20.36M derived: sum of 4 quarters · filed 2019-05-13 | |||
| 2018-12-31 | $4.85M derived: 10-K 12 month − 6-K 9 month · filed 2019-03-18 | $8.82M derived: sum of 2 quarters · filed 2019-03-18 | $13.04M derived: sum of 3 quarters · filed 2019-03-18 | $16.98M 10-K · filed 2019-03-18 | |||
| 2018-09-30 | $3.97M 6-K · filed 2018-11-07 | $8.19M derived: sum of 2 quarters · filed 2018-11-07 | $12.13M 6-K · filed 2018-11-07 | $16.49M derived: sum of 4 quarters · filed 2019-05-13 | |||
| 2018-06-30 | $4.22M 6-K · filed 2018-11-07 | $8.17M 6-K · filed 2018-09-28 | $12.52M derived: sum of 3 quarters · filed 2019-05-13 | $16.08M derived: sum of 4 quarters · filed 2019-05-13 | |||
| 2018-03-31 | $3.94M 10-Q · filed 2019-05-13 | $8.29M derived: sum of 2 quarters · filed 2019-05-13 | $11.86M derived: sum of 3 quarters · filed 2019-05-13 | $15.63M derived: sum of 4 quarters · filed 2019-05-13 | |||
| 2017-12-31 | $4.35M 6-K · filed 2018-11-07 | $3.03M 6-K · filed 2018-09-28 | $7.92M derived: sum of 2 quarters · filed 2018-11-07 | $11.69M derived: sum of 3 quarters · filed 2018-11-07 | $15.92M 10-K · filed 2019-03-18 | ||
| 2017-09-30 | $3.56M 6-K · filed 2018-11-07 | $4.89M 6-K · filed 2018-09-28 | $7.33M derived: sum of 2 quarters · filed 2018-11-07 | $11.56M 6-K · filed 2018-11-07 | |||
| 2017-06-30 | $3.77M 6-K · filed 2018-11-07 | $8.00M 6-K · filed 2018-09-28 | |||||
| 2017-03-31 | $4.23M 6-K · filed 2018-11-07 | ||||||
| 2016-12-31 | $17.93M 20-F · filed 2018-05-14 | $18.39M 20-F · filed 2017-04-28 | |||||
| 2015-12-31 | $5.48M 20-F · filed 2018-05-14 | $13.46M 20-F · filed 2016-03-04 | |||||
| 2014-12-31 | $25.11M 20-F · filed 2017-04-28 | ||||||
| 2013-12-31 | $7.07M 20-F · filed 2016-03-04 | $10.83M 20-F · filed 2014-03-28 | |||||
| 2012-12-31 | $818.00K 20-F · filed 2015-02-27 | ||||||
| 2011-12-31 | $1.82M 20-F · filed 2014-03-28 |